Sai Life Sciences Ltd's Q4FY25 Quarterly Results

Result Summary

• Sai Life Sciences Ltd reported a 1.4% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a - of -.
• Its expenses for the quarter were down by 2.8% QoQ and - - YoY.
• The net profit increased 4.2% QoQ and - - YoY.
• The earnings per share (EPS) of Sai Life Sciences Ltd stood at 3.1 during Q4FY25.

Financial Statments for Q4FY25

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Sai Life Sciences Ltd is a prominent player in the pharmaceutical industry, engaged primarily in the development and manufacturing of active pharmaceutical ingredients (APIs) and intermediates. The company is known for its focus on research and development, providing contract research and manufacturing services for global pharmaceutical companies. While specific recent developments are not available, Sai Life Sciences has been recognized for its contributions to the pharmaceutical sector, emphasizing innovation and quality in its offerings. The company operates in a competitive industry where regulatory compliance and technological advancements are key drivers of success.

Revenue

In the fourth quarter of fiscal year 2025 (Q4FY25), Sai Life Sciences Ltd reported a total income of ₹442.55 crores. This represents a slight decrease of 1.4% compared to the previous quarter (Q3FY25), where total income was ₹448.89 crores. The year-over-year comparison for total income is not available due to the absence of data for Q4FY24. The quarterly decline in revenue may reflect various operational or market factors affecting the company's income streams, although specific reasons are not detailed in the provided data.

Profitability

The profitability of Sai Life Sciences Ltd in Q4FY25 is highlighted by a profit before tax of ₹76.05 crores, which shows an increase of 6.1% from the previous quarter's figure of ₹71.65 crores. The profit after tax for Q4FY25 stood at ₹56.13 crores, marking a 4.2% rise from Q3FY25, where the profit after tax was ₹53.85 crores. The tax expense for Q4FY25 increased by 11.9% to ₹19.92 crores from ₹17.80 crores in Q3FY25. Earnings per share also saw an improvement, increasing by 10.7% to ₹3.10 from ₹2.80 in the previous quarter. This data indicates a positive trajectory in the company's profitability metrics on a quarter-over-quarter basis.

Operating Metrics

Operating expenses for Sai Life Sciences Ltd in Q4FY25 were recorded at ₹366.49 crores, reflecting a 2.8% decrease from Q3FY25, where expenses were ₹377.24 crores. The reduction in total expenses during the quarter correlates with the observed improvements in profitability. While the data does not provide specific details on the components contributing to this decrease, it suggests effective cost management during the quarter. Additionally, the absence of year-over-year data limits a broader historical comparison of operating metrics. The provided figures emphasize a focus on controlling operational expenses to support financial performance.